Constipation by Outlet ObstructionNCT04903470
Defecation Patterns in Constipated Patients
A study testing Bisacodyl and Atropin in people with Constipation by Outlet Obstruction, run by The California Medical Innovations Institute, Inc. at 2 sites in United States.
Trial summary
Chronic constipation (CC) is a common condition that affects up to 25% of the population in North America. It poses a major burden on the healthcare cost. The pathophysiology of this condition is poorly understood and consequently there are inadequate treatments. Read more about this study
- Who is it for?
- Ages 21 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Constipation by Outlet Obstruction
- What is being tested?
- Bisacodyl and Atropin
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 130 participants
- Where
- 2 sitesUnited States
- Study dates
- 19 Dec 2022to 30 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Rome IV diagnostic criteria will be used to diagnose chronic constipation. Patients must have experienced at least two of the following symptoms over the preceding 3 months:
- Fewer than three spontaneous bowel movements per week,
- Straining for more than 25% of defecation attempts,
- Lumpy or hard stools for at least 25% of defecation attempts, and
- sensation of anorectal obstruction or blockage.
- -
Who cannot join
- Subjects not willing to consent and undergo the specified tests in this study
- Pregnant women
- Subjects with concurrent fecal incontinence and constipation symptoms
- Chronic diseases
- Taking medications that affect anorectal function
- History of anorectal surgery or bowel resection.
Show all 10Show fewer
- Constipation patients:
- Patients not willing to consent and undergo the specified tests in this study
- pregnant women and patients with concurrent fecal incontinence
- History of anorectal surgery or bowel resection.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United States2 sites, 1 recruiting
- Recruiting
Augusta University Medical Center
Augusta, Georgia, 30912
Satish Rao, MD, PhD, 7067212238, srao@augusta.edu
- Active, not recruiting
California Medical Innovations Institute
San Diego, California, 92121
About this study
Official title: Understanding Defecation Patterns Using a Novel Device (Fecobionics) to Improve Treatment of Constipation
Chronic constipation (CC) is a common condition that affects up to 25% of the population in North America. It poses a major burden on the healthcare cost. The pathophysiology of this condition is poorly understood and consequently there are inadequate treatments. Current diagnostic tests provide incomplete and often conflicting information. Fecobionics is an electronic simulated stool that has the consistency and shape of normal stool. The device records pressures, cross-sectional area, orientation, bending, and shape of the rectum and anal canal simultaneously. The central hypothesis is that rectal peristalsis is a key component of the defecatory reflex which is not assessed in the current paradigm of diagnostic testing. The novel Fecobionics device will mimic the natural defecation and provide new mechanistic insights into the anorectal physiology and pathophysiology to facilitate the development of new treatments for CC. The Specific Aims are as follows: 1) Study the defecation dynamics in normal control subjects using Fecobionics. The investigators will establish the role of rectal contraction/peristalsis in the normal evacuation process. 2) Define the defecatory patterns in patients with CC associated with defecatory disorders. The investigators will determine if abnormalities of rectal contraction contribute to the CC. 3) Use a mathematical model of anorectal passage of Fecobionics for enhanced understanding of the normal and abnormal defecatory patterns, including the length-tension properties of the rectum and anal sphincter muscles. The proposal seeks to shift current CC research by providing a stool surrogate for examining the physiologic parameters of defecation reflex using a novel device that will record, pressure, deformability, biomechanics, vectoral and topographic changes in the rectum and anal canal. The noted parameters will be recorded using a wireless Fecobionics device that can examine in detail the mechanistic underpinnings (stress and deformation) of defecation reflex/process in health and disease. The impact of this project is that it assesses a novel, safe, low cost, less invasive, low-risk, radiation-free device in its ability to provide better understanding of evacuation and continence mechanisms and thereby facilitate future development of innovative therapies. The improvement can lead to improvement in diagnostic and therapeutic modalities and reduce healthcare costs associated with anorectal disorders.
Read the detailed description
For aim 1 study, the hypothesis is that a correctly performed Valsalva maneuver in the presence of an inflated bag (stool) in the rectum initiates the rectal peristaltic reflex that results in contraction of the rectal smooth muscles cranial to the bag and relaxation of the rectum and internal anal sphincter caudal to the bag. The Fecobionics device records rectal pressure as a surrogate of abdominal wall contraction. Changes in rectal pressure, however, can also be related to the contraction of the rectal smooth muscles. The proposed studies will record, 1) Abdominal wall EMG, and rectal wall ultrasound imaging, using high frequency ultrasound catheter probe to distinguish the contribution of abdominal muscle and rectal muscle contraction, respectively to the rectal pressure, 2) The investigators will study the effects of atropine to inhibit rectal smooth muscle contraction) on the Fecobionics expulsion, 3) EMG activity of the EAS during the Fecobionics device expulsion will allow determination of the role of EAS in the defecation reflex. For these studies, 3 separate experiments are proposed (15 normal healthy volunteers for each aim) to achieve above goals: 1) Record EAS and abdominal muscle EMG during the Fecobionics expulsion test: if the increase in intrarectal pressure is related entirely to the abdominal wall contraction, there will be a perfect spatiotemporal synchrony (not the amplitude) between the abdominal wall EMG and intrarectal pressure waveform as recorded by the cranial sensor of the Fecobionics device. Fecobionics and EMG signals can be recorded using wireless system in the private setting. 2) The investigators will record ultrasound images of the rectal wall using high frequency ultrasound catheter probe during Fecobionics balloon test. The investigators expect to observe an increase in the rectal smooth muscle thickness as a marker of active smooth muscle contraction during rectal peristalsis induced by the Valsalva maneuver. The ultrasound transducer will be placed at the location of the cranial sensor to visualize the ascending contraction of the peristaltic reflex (contraction cranial to the distended bag). 3) The investigators will perform Fecobionics expulsion test before and after administration of atropine I.V. 15micrograms/Kg. Only the rectal smooth muscle contraction-induced induced increases in the intrarectal pressure will be eliminated by atropine (not the abdominal wall skeletal muscle contraction).
For aim 2, The investigators will study 100 patients who meet Rome IV criteria for chronic constipation will be studied. Fecobionics recordings, along with US imaging of the rectal wall, EMG recordings of the abdominal wall and external anal sphincter will be performed, like the ones described in aim 1. In 15 subjects with CC, who fail to evacuate Fecobionics bag, The investigators will administer edrophonium (Tensilon) 80 μg/Kg) and repeat the Fecobionics expulsion test. Edrophonium increases the level of acetylcholine at the neuromuscular synapse to stimulate cholinergic activity and will be expected to stimulate rectal peristalsis and restore evacuation in patients with abnormalities of rectal peristalsis. In another 15 subjects with CC who fail to evacuate Fecobionics bag, The investigators will administer Bisacodyl (2 capsules, 10 mg, dissolved in 10 ml of saline) into the lumen of rectum through a tubing attached to the Fecobionics device. 5-10 minutes later the investigators will repeat the Fecobionics expulsion test. Bisacodyl is a stimulant laxative, used routinely in clinical practice. It works at the level of the enteric nerves to stimulate colon motility. The investigators will test the hypothesis that stimulation of rectal peristalsis by Bisacodyl restores the Fecobionics evacuation in patients with defecatory disorder related to the abnormalities of rectal peristalsis. Fecobionics, EMG and ultrasound image recordings, similar to what we described in Aim 1 of the study, will be able to assess all of essential elements of defecatory reflex. The investigators can assess them in a binary fashion whether absent or present. Based on the studies in normal individuals, however, we will determine the quantitative values of these parameters and compare them in patients as to which elements are in the abnormal range. The analysis will generate data to test the hypothesis that the following elements are part of the defecatory reflex: 1) Rectal distension by the stool/distended balloon causing an urge to defecate, 2) Correctly performed Valsalva maneuver that generates some critical threshold level of intra-abdominal pressure, 3) Rectal peristalsis that cause contraction above the balloon and relaxation of the internal anal sphincter and 4) Relaxation of the external anal sphincter and puborectalis muscle
Aim 3 studies will validate a mathematical model of the anorectal passage of the Fecobionics device to predict the occurrence/non-occurrence of the event in question. In order to build a successful model, it is critical to know all the variables or parameters involved in the occurrence of any event. Defecation/evacuation is basically the motion of liquid/ solid material from rectum across the anal canal to the outside. The two important players in the evacuation process are the intrarectal pressure (driving force) and resistive force. The intrarectal pressure can be generated by abdominal wall contraction and/or rectal muscle contraction related increases in rectal pressure. On the other hand, resistive forces for the evacuation are related to the IAS, EAS, puborectalis muscle and frictional forces. Fecobionics data along with the US imaging data, EMG recordings of abdominal wall and EAS, for the first time should provide all the players involved in the defecation process. The investigators will be collecting data from the normal subjects and patients which can be plugged into a mathematical equation to predict successful event. However, above would only be possible if all the elements in the defecation/evacuation process are known. The purpose of the modelling experiment will be to determine if the assumption of known elements of the process of defecation can predict it correctly. For example, whether anorectal angle is critical for the continence/ incontinence function has never been addressed and the hope is that using modelling approach we will be able to determine if the above is correct, which can also be true for the other variables that we will record.
- Conditions
- Constipation by Outlet Obstruction
- Being tested
- Bisacodyl, Atropin
- Keywords
- Obstructed defecation, Pelvic floor dysynergia, Paradoxical contraction of the anal sphincter, Anorectal motility, Impedance planimetry of anal sphincter
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BisacodylDrug
Also called Effect of bisacodyl on the expulsion of rectal balloon (fecobionics device)
Biscodyl a stimulant laxative is expected to stimulate rectal contraction and enhance expulsion of Fecobionics
AtropinDrug
Atropin is an anticholinergic drug that is expected to inhibit rectal contractions and make defecation more difficult.
| Study group | Role | What they receive |
|---|---|---|
| Effect of atropine on the defecation | Experimental | Atropine is an anticholinergic drug and expected to inhibit rectal contractions and inhibit evacuation of the rectal balloon. Each subject will be studied twice once with and once without atropine. Receives: Drug: Atropin |
| Effect of bisacodyl on the defecation | Experimental | Bisacodyl is a stimulant of rectal contraction and expected to facilitate evacuation of rectal balloon (fecobionics device). Each subject will be studied twice, once with and once without bisacodyl. Receives: Drug: Bisacodyl |
What is being measured
The primary outcome is the main question the study is designed to answer.
Evacuation duration of rectal balloon.
Evacuation duration is the time it takes from evacuation is initiated until the balloon is expelled. Change from the evacuation duration baseline induced by atropine and bisacodyl.
Measured: 3 years
Secondary outcomes (2)
Rectal contraction pressure.
Rectal contractions, i.e. increase in pressure, will be induced by balloon distension. Change in the rectal pressure baseline induced by Atropine and bisacodyl.
Measured: 3 years
Anorectal angle.
The anorectal angle is the angle between the direction of the anal canal and rectum. Change in baseline anorectal angle induced by atropine and bisacodyl.
Measured: 4 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 May 2021
- Study start19 Dec 2022
- Primary completion30 Dec 2026 (estimated)
- Study completion30 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Constipation by Outlet ObstructionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- In this crossover study, the subjects receive from one drug up to a sequence of drugs such as atropine and edrophonium to study the effect on defecatory mechanisms.
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 130 participants (estimated)
Sponsor and investigators
- Lead sponsor
- The California Medical Innovations Institute, Inc.
- Sponsor type
- University, hospital or other
- Collaborators
- Augusta University
- Responsible party
- Principal investigator, Hans Gregersen, PhD, The California Medical Innovations Institute, Inc.
- Investigators
- Hans Gregersen, MD, PhD, Principal investigator, California Medical Innovations Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04903470
- Sponsor's protocol ID
- CALM-CLIN-2025-edited
- Status last verified
- Oct 2025
- First submitted
- 6 May 2021
- Last updated
- 21 Oct 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Oct 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Understanding Defecation Patterns Using a Novel Device (Fecobionics) to Improve Treatment of Constipation
- ClinicalTrials.gov ID
- NCT04903470
- Acronym / sponsor ID
- CALM-CLIN-2025-edited
- Conditions
- Constipation by Outlet Obstruction
- Keywords
- Obstructed defecation, Pelvic floor dysynergia, Paradoxical contraction of the anal sphincter, Anorectal motility, Impedance planimetry of anal sphincter
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 130 participants (estimated)
- Lead sponsor
- The California Medical Innovations Institute, Inc.University, hospital or other
- Collaborators
- Augusta University
- Study start
- 19 Dec 2022 (actual)
- Primary completion
- 30 Dec 2026 (estimated)
- Study completion
- 30 Dec 2026 (estimated)
- First posted
- 26 May 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Chronic constipation (CC) is a common condition that affects up to 25% of the population in North America. It poses a major burden on the healthcare cost. The pathophysiology of this condition is poorly understood and consequently there are inadequate treatments. Current diagnostic tests provide incomplete and often conflicting information. Fecobionics is an electronic simulated stool that has the consistency and shape of normal stool. The device records pressures, cross-sectional area, orientation, bending, and shape of the rectum and anal canal simultaneously. The central hypothesis is that rectal peristalsis is a key component of the defecatory reflex which is not assessed in the current paradigm of diagnostic testing. The novel Fecobionics device will mimic the natural defecation and provide new mechanistic insights into the anorectal physiology and pathophysiology to facilitate the development of new treatments for CC. The Specific Aims are as follows: 1) Study the defecation dynamics in normal control subjects using Fecobionics. The investigators will establish the role of rectal contraction/peristalsis in the normal evacuation process. 2) Define the defecatory patterns in patients with CC associated with defecatory disorders. The investigators will determine if abnormalities of rectal contraction contribute to the CC. 3) Use a mathematical model of anorectal passage of Fecobionics for enhanced understanding of the normal and abnormal defecatory patterns, including the length-tension properties of the rectum and anal sphincter muscles. The proposal seeks to shift current CC research by providing a stool surrogate for examining the physiologic parameters of defecation reflex using a novel device that will record, pressure, deformability, biomechanics, vectoral and topographic changes in the rectum and anal canal. The noted parameters will be recorded using a wireless Fecobionics device that can examine in detail the mechanistic underpinnings (stress and deformation) of defecation reflex/process in health and disease. The impact of this project is that it assesses a novel, safe, low cost, less invasive, low-risk, radiation-free device in its ability to provide better understanding of evacuation and continence mechanisms and thereby facilitate future development of innovative therapies. The improvement can lead to improvement in diagnostic and therapeutic modalities and reduce healthcare costs associated with anorectal disorders.
Detailed description
For aim 1 study, the hypothesis is that a correctly performed Valsalva maneuver in the presence of an inflated bag (stool) in the rectum initiates the rectal peristaltic reflex that results in contraction of the rectal smooth muscles cranial to the bag and relaxation of the rectum and internal anal sphincter caudal to the bag. The Fecobionics device records rectal pressure as a surrogate of abdominal wall contraction. Changes in rectal pressure, however, can also be related to the contraction of the rectal smooth muscles. The proposed studies will record, 1) Abdominal wall EMG, and rectal wall ultrasound imaging, using high frequency ultrasound catheter probe to distinguish the contribution of abdominal muscle and rectal muscle contraction, respectively to the rectal pressure, 2) The investigators will study the effects of atropine to inhibit rectal smooth muscle contraction) on the Fecobionics expulsion, 3) EMG activity of the EAS during the Fecobionics device expulsion will allow determination of the role of EAS in the defecation reflex. For these studies, 3 separate experiments are proposed (15 normal healthy volunteers for each aim) to achieve above goals: 1) Record EAS and abdominal muscle EMG during the Fecobionics expulsion test: if the increase in intrarectal pressure is related entirely to the abdominal wall contraction, there will be a perfect spatiotemporal synchrony (not the amplitude) between the abdominal wall EMG and intrarectal pressure waveform as recorded by the cranial sensor of the Fecobionics device. Fecobionics and EMG signals can be recorded using wireless system in the private setting. 2) The investigators will record ultrasound images of the rectal wall using high frequency ultrasound catheter probe during Fecobionics balloon test. The investigators expect to observe an increase in the rectal smooth muscle thickness as a marker of active smooth muscle contraction during rectal peristalsis induced by the Valsalva maneuver. The ultrasound transducer will be placed at the location of the cranial sensor to visualize the ascending contraction of the peristaltic reflex (contraction cranial to the distended bag). 3) The investigators will perform Fecobionics expulsion test before and after administration of atropine I.V. 15micrograms/Kg. Only the rectal smooth muscle contraction-induced induced increases in the intrarectal pressure will be eliminated by atropine (not the abdominal wall skeletal muscle contraction).
For aim 2, The investigators will study 100 patients who meet Rome IV criteria for chronic constipation will be studied. Fecobionics recordings, along with US imaging of the rectal wall, EMG recordings of the abdominal wall and external anal sphincter will be performed, like the ones described in aim 1. In 15 subjects with CC, who fail to evacuate Fecobionics bag, The investigators will administer edrophonium (Tensilon) 80 μg/Kg) and repeat the Fecobionics expulsion test. Edrophonium increases the level of acetylcholine at the neuromuscular synapse to stimulate cholinergic activity and will be expected to stimulate rectal peristalsis and restore evacuation in patients with abnormalities of rectal peristalsis. In another 15 subjects with CC who fail to evacuate Fecobionics bag, The investigators will administer Bisacodyl (2 capsules, 10 mg, dissolved in 10 ml of saline) into the lumen of rectum through a tubing attached to the Fecobionics device. 5-10 minutes later the investigators will repeat the Fecobionics expulsion test. Bisacodyl is a stimulant laxative, used routinely in clinical practice. It works at the level of the enteric nerves to stimulate colon motility. The investigators will test the hypothesis that stimulation of rectal peristalsis by Bisacodyl restores the Fecobionics evacuation in patients with defecatory disorder related to the abnormalities of rectal peristalsis. Fecobionics, EMG and ultrasound image recordings, similar to what we described in Aim 1 of the study, will be able to assess all of essential elements of defecatory reflex. The investigators can assess them in a binary fashion whether absent or present. Based on the studies in normal individuals, however, we will determine the quantitative values of these parameters and compare them in patients as to which elements are in the abnormal range. The analysis will generate data to test the hypothesis that the following elements are part of the defecatory reflex: 1) Rectal distension by the stool/distended balloon causing an urge to defecate, 2) Correctly performed Valsalva maneuver that generates some critical threshold level of intra-abdominal pressure, 3) Rectal peristalsis that cause contraction above the balloon and relaxation of the internal anal sphincter and 4) Relaxation of the external anal sphincter and puborectalis muscle
Aim 3 studies will validate a mathematical model of the anorectal passage of the Fecobionics device to predict the occurrence/non-occurrence of the event in question. In order to build a successful model, it is critical to know all the variables or parameters involved in the occurrence of any event. Defecation/evacuation is basically the motion of liquid/ solid material from rectum across the anal canal to the outside. The two important players in the evacuation process are the intrarectal pressure (driving force) and resistive force. The intrarectal pressure can be generated by abdominal wall contraction and/or rectal muscle contraction related increases in rectal pressure. On the other hand, resistive forces for the evacuation are related to the IAS, EAS, puborectalis muscle and frictional forces. Fecobionics data along with the US imaging data, EMG recordings of abdominal wall and EAS, for the first time should provide all the players involved in the defecation process. The investigators will be collecting data from the normal subjects and patients which can be plugged into a mathematical equation to predict successful event. However, above would only be possible if all the elements in the defecation/evacuation process are known. The purpose of the modelling experiment will be to determine if the assumption of known elements of the process of defecation can predict it correctly. For example, whether anorectal angle is critical for the continence/ incontinence function has never been addressed and the hope is that using modelling approach we will be able to determine if the above is correct, which can also be true for the other variables that we will record.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (participant)
- Number of arms
- 2
- Model description
- In this crossover study, the subjects receive from one drug up to a sequence of drugs such as atropine and edrophonium to study the effect on defecatory mechanisms.
| Arm | Type | Receives |
|---|---|---|
| Effect of atropine on the defecation | Experimental | Drug: AtropinAtropine is an anticholinergic drug and expected to inhibit rectal contractions and inhibit evacuation of the rectal balloon. Each subject will be studied twice once with and once without atropine. |
| Effect of bisacodyl on the defecation | Experimental | Drug: BisacodylBisacodyl is a stimulant of rectal contraction and expected to facilitate evacuation of rectal balloon (fecobionics device). Each subject will be studied twice, once with and once without bisacodyl. |
Who may qualify
- Ages
- 21 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Rome IV diagnostic criteria will be used to diagnose chronic constipation. Patients must have experienced at least two of the following symptoms over the preceding 3 months:
- -
Key exclusion criteria (10 listed)
- Subjects not willing to consent and undergo the specified tests in this study
- Pregnant women
- Subjects with concurrent fecal incontinence and constipation symptoms
- Chronic diseases
- Taking medications that affect anorectal function
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| BisacodylAlso: Effect of bisacodyl on the expulsion of rectal balloon (fecobionics device)Biscodyl a stimulant laxative is expected to stimulate rectal contraction and enhance expulsion of Fecobionics | Drug | Effect of bisacodyl on the defecation |
| AtropinAtropin is an anticholinergic drug that is expected to inhibit rectal contractions and make defecation more difficult. | Drug | Effect of atropine on the defecation |
Primary outcome
Evacuation duration of rectal balloon.
Time frame: 3 years
Evacuation duration is the time it takes from evacuation is initiated until the balloon is expelled. Change from the evacuation duration baseline induced by atropine and bisacodyl.
2 secondary outcomes
Rectal contraction pressure.
Time frame: 3 years
Anorectal angle.
Time frame: 4 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Oct 2025.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Hans Gregersen, MD, PhD principal investigator
California Medical Innovations Institute
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Bisacodyl and Atropin in people with Constipation by Outlet Obstruction, run by The California Medical Innovations Institute, Inc. at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 21 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hans Gregersen,, PhD (858-249-7400, hag@giome.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evacuation duration of rectal balloon. (time frame: 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Oct 2025; AzTrials last refreshed its copy on 27 Oct 2026.